PharmaEssentia Corporation (TPE: 6446)

Market Cap	228.69B
Revenue (ttm)	8.32B
Net Income (ttm)	1.85B
Shares Out	332.89M
EPS (ttm)	5.54
PE Ratio	123.98
Forward PE	41.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,353,479
Average Volume	2,370,928
Open	698.00
Previous Close	693.00
Day's Range	684.00 - 702.00
52-Week Range	281.00 - 735.00
Beta	0.57
RSI	57.44
Earnings Date	Feb 27, 2025

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 131
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6446

Financial Performance

In 2023, PharmaEssentia's revenue was 5.11 billion, an increase of 77.15% compared to the previous year's 2.88 billion. Losses were -623.84 million, -54.62% less than in 2022.